Stock listing
NYSE:ADCT ADC Therapeutics SA Stock
Home listing (NYSE) of ADC Therapeutics SA
Follow ADC Therapeutics SA into a list and get an email when it puts out news.
Share price · NYSE:ADCT
$1.28 USD -0.09 (-6.6%)
Close on Nov 20, 2026
- Day range
- $1.26 – $1.36 USDNov 20, 2026
- Volume
- 1.10M sharesNov 20, 2026
- Market cap
- $163.4M USDAt the close on Nov 20, 2026 · price × 127.7M shares outstanding
- 52-week range
- $0.78 – $4.98 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.13M USDMedian day 1.30M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:ADCT · Home | $1.28 USD | -0.09 (-6.6%) | 1,095,383 | $1.29 | $1.355 | $1.256 | $1.37 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:ADCT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.28 | -0.09 | -6.6% | $1.29 | $1.355 | $1.256 | 1,095,383 | |
| $1.37 | +0.02 | +1.5% | $1.34 | $1.41 | $1.31 | 1,170,139 | |
| $1.35 | +0.10 | +8.0% | $1.25 | $1.42 | $1.24 | 1,097,091 | |
| $1.25 | -0.09 | -6.7% | $1.32 | $1.35 | $1.24 | 1,480,579 | |
| $1.34 | -0.07 | -5.0% | $1.41 | $1.43 | $1.28 | 1,073,024 | |
| $1.41 | -0.19 | -11.9% | $1.58 | $1.58 | $1.40 | 1,871,580 | |
| $1.60 | +0.09 | +6.0% | $1.50 | $1.615 | $1.43 | 767,331 | |
| $1.51 | -0.16 | -9.6% | $1.62 | $1.73 | $1.475 | 1,304,537 | |
| $1.67 | +0.09 | +5.7% | $1.65 | $1.72 | $1.405 | 2,382,657 | |
| $1.58 | -0.06 | -3.7% | $1.63 | $1.64 | $1.515 | 810,103 | |
| $1.64 | -0.08 | -4.7% | $1.73 | $1.74 | $1.61 | 1,724,606 | |
| $1.72 | +0.17 | +11.0% | $1.61 | $1.865 | $1.61 | 4,304,356 | |
| $1.55 | +0.01 | +0.6% | $1.58 | $1.66 | $1.53 | 865,885 | |
| $1.54 | +0.01 | +0.7% | $1.58 | $1.675 | $1.50 | 1,071,483 | |
| $1.53 | +0.04 | +2.7% | $1.49 | $1.54 | $1.43 | 1,175,387 | |
| $1.49 | -0.13 | -8.0% | $1.67 | $1.70 | $1.49 | 899,752 | |
| $1.62 | +0.03 | +1.9% | $1.59 | $1.63 | $1.545 | 607,765 | |
| $1.59 | +0.08 | +5.3% | $1.49 | $1.60 | $1.46 | 1,250,598 | |
| $1.51 | +0.07 | +4.9% | $1.45 | $1.54 | $1.43 | 1,048,540 | |
| $1.44 | -0.16 | -10.0% | $1.58 | $1.585 | $1.43 | 1,045,600 | |
| $1.60 | +0.10 | +6.7% | $1.50 | $1.62 | $1.479 | 824,844 | |
| $1.50 | -0.02 | -1.3% | $1.53 | $1.555 | $1.44 | 1,328,331 | |
| $1.52 | +0.08 | +5.6% | $1.45 | $1.55 | $1.43 | 1,057,352 | |
| $1.44 | +0.04 | +2.9% | $1.40 | $1.49 | $1.39 | 575,619 | |
| $1.40 | -0.09 | -6.0% | $1.49 | $1.51 | $1.40 | 799,525 | |
| $1.49 | +0.04 | +2.8% | $1.47 | $1.565 | $1.46 | 1,331,061 | |
| $1.45 | -0.25 | -14.7% | $1.67 | $1.725 | $1.40 | 1,741,916 | |
| $1.70 | -0.16 | -8.6% | $1.86 | $1.86 | $1.625 | 3,325,278 | |
| $1.86 | +0.13 | +7.5% | $1.70 | $1.87 | $1.64 | 1,593,120 | |
| $1.73 | +0.14 | +8.8% | $1.58 | $1.83 | $1.56 | 3,143,187 | |
| $1.59 | +0.17 | +12.0% | $1.41 | $1.63 | $1.32 | 5,552,486 | |
| $1.42 | +0.15 | +11.8% | $1.25 | $1.44 | $1.235 | 1,750,770 | |
| $1.27 | +0.04 | +3.3% | $1.25 | $1.27 | $1.20 | 1,352,795 | |
| $1.23 | +0.10 | +8.8% | $1.12 | $1.26 | $1.11 | 1,752,161 | |
| $1.13 | +0.05 | +4.6% | $1.10 | $1.14 | $1.06 | 1,320,588 | |
| $1.08 | -0.14 | -11.5% | $1.20 | $1.201 | $1.07 | 862,274 | |
| $1.22 | -0.01 | -0.8% | $1.23 | $1.285 | $1.20 | 1,111,965 | |
| $1.23 | -0.03 | -2.4% | $1.27 | $1.29 | $1.20 | 781,015 | |
| $1.26 | -0.01 | -0.8% | $1.24 | $1.27 | $1.20 | 835,119 | |
| $1.27 | -0.02 | -1.6% | $1.26 | $1.285 | $1.21 | 1,076,982 | |
| $1.29 | -0.02 | -1.5% | $1.305 | $1.31 | $1.24 | 1,575,647 | |
| $1.31 | +0.08 | +6.5% | $1.24 | $1.32 | $1.21 | 1,972,380 | |
| $1.23 | +0.11 | +9.8% | $1.13 | $1.25 | $1.12 | 1,674,295 | |
| $1.12 | +0.07 | +6.7% | $1.05 | $1.13 | $1.035 | 1,899,275 | |
| $1.05 | -0.01 | -0.9% | $1.06 | $1.145 | $1.05 | 1,577,209 | |
| $1.06 | +0.01 | +1.0% | $1.06 | $1.10 | $1.01 | 1,545,569 | |
| $1.05 | -0.04 | -3.7% | $1.09 | $1.095 | $1.025 | 3,316,970 | |
| $1.09 | -0.02 | -1.8% | $1.12 | $1.12 | $1.03 | 1,259,823 | |
| $1.11 | +0.04 | +3.7% | $1.07 | $1.12 | $1.06 | 808,479 | |
| $1.07 | -0.04 | -3.6% | $1.13 | $1.156 | $1.04 | 989,105 | |
| $1.11 | -0.11 | -9.0% | $1.21 | $1.24 | $1.07 | 957,194 | |
| $1.22 | -0.08 | -6.2% | $1.28 | $1.31 | $1.191 | 1,709,284 | |
| $1.30 | -0.06 | -4.4% | $1.33 | $1.35 | $1.27 | 930,761 | |
| $1.36 | +0.04 | +3.0% | $1.30 | $1.37 | $1.30 | 1,478,303 | |
| $1.32 | 0.00 | 0.0% | $1.32 | $1.37 | $1.30 | 2,774,762 | |
| $1.32 | +0.08 | +6.5% | $1.23 | $1.35 | $1.23 | 1,955,644 | |
| $1.24 | +0.07 | +6.0% | $1.15 | $1.24 | $1.14 | 1,149,641 | |
| $1.17 | +0.03 | +2.6% | $1.13 | $1.19 | $1.125 | 1,251,778 | |
| $1.14 | +0.02 | +1.8% | $1.11 | $1.17 | $1.07 | 2,577,910 | |
| $1.12 | +0.07 | +6.7% | $1.05 | $1.14 | $1.05 | 1,403,771 | |
| $1.05 | +0.01 | +1.0% | $1.04 | $1.075 | $1.01 | 1,947,239 | |
| $1.04 | +0.075 | +7.8% | $0.976 | $1.05 | $0.96 | 3,927,974 | |
| $0.965 | -0.032 | -3.2% | $0.99 | $1.00 | $0.951 | 640,512 | |
| $0.997 | +0.037 | +3.8% | $0.974 | $1.00 | $0.97 | 1,088,237 | |
| $0.96 | -0.08 | -7.7% | $1.02 | $1.04 | $0.95 | 2,422,878 |
- Ticker
- NYSE:ADCT
- Asset type
- Stock
- Exchange
- NYSE
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates
Latest earnings call · Aug 13, 2026
ADC Therapeutics (NYSE:ADCT) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Corporate Update (November 2026)
Corporate update · 18 slides
Latest news
ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates
Nov 9, 2026
Closed $1.67 (+5.7%) on Nov 9, 2026
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
Nov 4, 2026
Closed $1.72 (+11.0%) on Nov 4, 2026
ADC Therapeutics to Present at November Investor Conferences
Nov 3, 2026
Closed $1.55 (+0.6%) on Nov 3, 2026
ADC Therapeutics Announces New Employee Inducement Grant
Nov 2, 2026
Closed $1.55 (+0.6%) on Nov 3, 2026
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
Nov 2, 2026
Closed $1.54 (+0.7%) on Nov 2, 2026
ADC Therapeutics Announces ZYNLONTA® Updates in Japan
Oct 29, 2026
Closed $1.49 (-8.0%) on Oct 29, 2026
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
Oct 8, 2026
Closed $1.59 (+12.0%) on Oct 8, 2026
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Sep 3, 2026
Closed $1.32 (0.0%) on Sep 3, 2026
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
Aug 13, 2026
Closed $1.05 (-14.6%) on Aug 13, 2026
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
Aug 6, 2026
Closed $1.13 (+5.6%) on Aug 6, 2026
ADC Therapeutics SA on 6ix
- News releases
- 25 in the last 12 months · 45 in all · newest Nov 9, 2026 · oldest 2025
- Calls
- 25 calls with a replay · 25 with a transcript · latest Aug 13, 2026
- Decks
- 40 decks · latest Nov 4, 2026
Where ADC Therapeutics SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:ADCT · Home listing · This page | NYSE | United States | USD |
| BOATS:ADCT | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$17.99M USD
- P/E
- Loss
- EV/sales
- −0.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 86.8%
- Operating margin
- −97.7%
- Net margin
- −95.7%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.49
Forecasts
3 strong buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 3.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.75 · 4 analysts
- Revenue, year to Dec 2026
- 80.56M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ameet Mallik | Chief Executive Officer |
| Jose Carmona | Chief Financial Officer |
| Peter Graham | Chief Legal Officer |
| David Ege | Chief Technical Officer |
| Kimberly Pope | Chief People Officer |
| Kristen Harrington-Smith | Chief Commercial Officer |
| Mohamed Zaki | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Ron Squarer | Chairman |
| Bob Azelby | Non-Executive Director |
| Jean-Pierre Bizzari | Non-Executive Director |
| Peter Hug | Vice-Chairman and Lead Independent Director |
| Tim Coughlin | Non-Executive Director |
| Tyrell J. Rivers | Non-Executive Director |
| Victor Sandor | Non-Executive Director |
| Viviane Monges | Non-Executive Director |
Events
- Next results
- Mar 10, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| ADC Therapeutics (NYSE:ADCT) Q2 2026 Earnings Call | Thu, Aug 13, 2026 · 8:30 AM ET | Replay |
| ADC Therapeutics (NYSE:ADCT) Q1 2026 Earnings Call | Mon, May 04, 2026 · 8:30 AM ET | Replay |
| ADC Therapeutics (NYSE:ADCT) Q4 2025 Earnings Call | Tue, Mar 10, 2026 · 8:30 AM ET | Replay |
| ADC Therapeutics (NYSE:ADCT) Q3 2025 Earnings Call | Mon, Nov 10, 2025 · 8:30 AM ET | Replay |
| ADC Therapeutics (NYSE:ADCT) Q2 2025 Earnings Call | Tue, Aug 12, 2025 · 8:30 AM ET | Replay |
| ADC Therapeutics (NYSE:ADCT) Q1 2025 Earnings Call | Wed, May 14, 2025 · 8:30 AM ET | Replay |
| ADC Therapeutics (NYSE:ADCT) Q4 2024 Earnings Call | Thu, Mar 27, 2025 · 8:30 AM ET | Replay |
| ADC Therapeutics (NYSE:ADCT) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 8:30 AM ET | Replay |
| ADC Therapeutics (NYSE:ADCT) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 8:30 AM ET | Replay |
| ADC Therapeutics (NYSE:ADCT) Q1 2024 Earnings Call | Mon, May 06, 2024 · 8:30 AM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +5.7% |
| Q2 2026 | Aug 13, 2026 · Before open | −14.6% |
| Q1 2026 | May 4, 2026 · Before open | −3.9% |
| Q4 2025 | Mar 12, 2026 | −15.4% |
| Q3 2025 | Nov 10, 2025 · Before open | +4.2% |
| Q2 2025 | Aug 12, 2025 · Before open | +9.7% |
| Q1 2025 | May 5, 2025 · Before open | −1.4% |
| Q4 2024 | Mar 27, 2025 · Before open | −3.8% |
| Q3 2024 | Nov 7, 2024 · Before open | −8.4% |
| Q2 2024 | Aug 6, 2024 · Before open | +1.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · Before open | −9.2% |
| Q4 2023 | Mar 13, 2024 · Before open | −12.4% |
| Q3 2023 | Nov 7, 2023 · Before open | −16.0% |
| Q2 2023 | Aug 8, 2023 · Before open | +11.9% |
| Q1 2023 | May 9, 2023 · Before open | +2.4% |
| Q4 2022 | Feb 28, 2023 · Before open | −11.6% |
| Q3 2022 | Nov 8, 2022 · Before open | −2.8% |
| Q2 2022 | Aug 9, 2022 · Before open | −1.0% |
| Q1 2022 | May 9, 2022 · Before open | −28.7% |
| Q4 2021 | Mar 3, 2022 · Before open | −8.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 18 slides | Nov 4, 2026 |
| Investor Presentation (November 2026) | Investor deck | 25 slides | November 2026 |
| Q2 2026 Earnings Presentation | Earnings | 9 slides | Aug 13, 2026 |
| Investor Presentation (August 2026) | Investor deck | 62 slides | August 2026 |
| Technical Presentation (June 2026) | Technical | 29 slides | Jun 3, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 9 slides | May 4, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 15 slides | Mar 10, 2026 |
| Investor Presentation (January 2026) | Investor deck | 28 slides | Jan 12, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 13 slides | Nov 10, 2025 |
| Investor Presentation (October 2025) | Investor deck | 28 slides | Oct 14, 2025 |
All 40 decks
Financings
| Raise | Date |
|---|---|
| Private placement of common shares and pre-funded warrants Announced: US$86.6M · US$1.42 a share · Jefferies +2 Dealers: Jefferies, Guggenheim Securities, Cantor Buyers: Bain Capital Life Sciences; Redmile; TCGX; Nantahala Capital Use of proceeds: Fund ZYNLONTA pipeline studies including Phase 3 trials in DLBCL and MZL, strengthen the balance sheet, working capital and general corporate purposes | Oct 8, 2026 |
| Private placement of equity securities Closed: US$60M raised · US$4 a share · Jefferies Dealers: Jefferies (lead) Buyers: TCGX; Redmile Group Use of proceeds: Fund the commercial expansion of ZYNLONTA and strengthen the balance sheet | Nov 10, 2025 |
| Private placement of common shares and pre-funded warrants Announced: US$100M · US$3.53 a share · Jefferies +3 Dealers: Jefferies, Guggenheim Securities, Cantor, RBC Capital Markets Buyers: Redmile Group (led the PIPE) Use of proceeds: ZYNLONTA clinical development and commercialization, working capital and general corporate purposes | Jun 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$19.00 a share on May 14, 2020.
- Price
- US$19.00 a share
- Shares offered
- 12,245,631 common shares
- Offering size
- US$232.7 million
- Underwriters' option
- Up to 1,836,844 more shares
- Listing
- ADCT on the New York Stock Exchange
- Underwriters
- MORGAN STANLEY, BofA SECURITIES, COWEN · In the order on the cover
- Shares delivered
- On or about May 19, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 2, 2020 |
| Filed publicly | Apr 24, 2020 |
| Amended 3 times | Newest May 14, 2020 |
| Shares registered with an exchange | May 11, 2020 |
| Declared effective by the SEC | May 14, 2020 |
| Final prospectus, with the price | May 18, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 18, 2020 |
| EFFECT · Notice that a registration is effective | May 14, 2020 |
| F-1MEF · Registration of more shares for the same offering | May 14, 2020 |
| F-1/A · Registration statement, amended | May 14, 2020 |
| CERT · Exchange's certificate of listing | May 12, 2020 |
| CORRESP · Letter to the SEC | May 12, 2020 |
| CORRESP · Letter to the SEC | May 12, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | May 11, 2020 |
| F-1/A · Registration statement, amended | May 11, 2020 |
| CORRESP · Letter to the SEC | Apr 28, 2020 |
All 15 filings
| Filing | Filed |
|---|---|
| F-1/A · Registration statement, amended | Apr 27, 2020 |
| F-1 · Registration statement | Apr 24, 2020 |
| UPLOAD · Letter from the SEC | Mar 25, 2020 |
| DRSLTR · Letter to the SEC with a draft | Mar 2, 2020 |
| DRS · Draft registration statement | Mar 2, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed May 18, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.4M | 70.8M | 69.6M | 209.9M | 33.9M | 0 | 2.34M | 1.14M | 1.80M |
| Cost of revenue | 5.80M | 5.95M | 2.53M | 3.30M | 1.39M | 141.8M | 107.5M | 118.1M | 85.5M |
| Gross profit | 73.7M | 64.9M | 67.0M | 206.6M | 32.5M | -141.8M | 2.34M | -116.9M | -83.7M |
| Research and development | 104.0M | 109.6M | 127.1M | 186.5M | 158.0M | 142.0M | 107.5M | 118.3M | 85.5M |
| Selling, general and administrative | 36.6M | 64.5M | 72.9M | 107.7M | 71.5M | 55.1M | 14.2M | 8.60M | 7.81M |
| Operating income | -121.5M | -130.7M | -166.0M | -123.3M | -261.7M | -219.3M | -119.4M | -125.9M | -91.7M |
| Depreciation and amortization | 705.0K | 1.33M | 1.19M | 1.06M | 2.63M | 1.97M | 1.65M | 740.0K | 341.0K |
| EBITDA | -120.8M | -129.3M | -164.8M | -122.3M | -259.1M | -217.3M | -117.8M | -125.2M | -91.3M |
| Interest expense | 51.6M | 50.2M | 46.3M | 36.7M | 18.3M | 4.93M | 156.0K | 3.28M | 2.68M |
| Income before tax | -141.6M | -156.1M | -195.4M | -146.8M | -251.5M | -246.0M | -115.9M | -122.9M | -89.8M |
| Income tax | 1.01M | 166.0K | 39.1M | 227.0K | -21.5M | 327.0K | 582.0K | 224.0K | 48.0K |
| Net income | -142.6M | -157.8M | -240.1M | -157.1M | -230.0M | -246.3M | -116.5M | -123.1M | -89.9M |
| Earnings per share, basic | -1.12 | -1.62 | -2.94 | -2.01 | -3.00 | -3.77 | -1.74 | -2.29 | -1.53 |
| Earnings per share, diluted | -1.12 | -1.62 | -2.94 | -2.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 261.3M | 250.9M | 278.6M | 326.4M | 466.5M | 439.2M | 115.6M | 138.8M | 262.8M | 143.7M |
| Receivables | 29.1M | 20.3M | 25.2M | 73.0M | 31.1M | 2.69M | 2.84M | 372.0K | 1.93M | 5.91M |
| Inventory | 4.18M | 2.25M | 16.2M | 12.1M | 11.1M | 6.50M | 2.47M | 1.20M | 293.0K | |
| Current assets | 306.3M | 291.3M | 336.3M | 435.0M | 525.2M | 450.4M | 122.6M | 142.1M | 265.2M | 151.3M |
| Property, plant and equipment | 0 | 5.08M | 5.62M | 3.35M | 11.2M | 4.76M | 6.27M | 1.54M | 1.14M | |
| Total assets | 323.1M | 322.0M | 354.8M | 490.9M | 618.0M | 513.7M | 137.7M | 150.6M | 271.9M | 155.1M |
| Accounts payable | 9.18M | 18.0M | 15.6M | 12.4M | 12.1M | 5.28M | 3.33M | 6.75M | 7.62M | 2.15M |
| Current liabilities | 70.2M | 80.5M | 67.7M | 81.9M | 73.9M | 40.4M | 19.9M | 22.4M | 20.5M | 9.67M |
| Long-term debt | 112.5M | 113.6M | 112.7M | 97.2M | 125.1M | 108.0M | ||||
| Total debt | 3.00M | 0 | 124.4M | 129.8M | 139.7M | 115.1M | 5.03M | |||
| Total liabilities | 509.0M | 524.6M | 503.0M | 411.4M | 451.9M | 178.2M | 26.5M | 24.3M | 22.8M | 14.2M |
| Shareholders' equity | -185.8M | -202.6M | -148.2M | 79.5M | 166.1M | 335.5M | 111.2M | 126.2M | 249.2M | 140.9M |
| Shares outstanding | 125.7M | 98.9M | 82.3M | 80.6M | 76.7M | 65.4M | 66.9M | 53.8M | 58.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -141.2M | -123.8M | -118.7M | -138.3M | -233.4M | -168.7M | -121.6M | -121.4M | -74.9M |
| Capital spending | -264.0K | -867.0K | -3.22M | -687.0K | -6.38M | -2.81M | -2.15M | -2.47M | -3.16M |
| Free cash flow | -141.4M | -124.7M | -121.9M | -139.0M | -239.8M | -171.5M | -123.7M | -123.8M | -78.1M |
| Cash from investing | 395.0K | -867.0K | -3.22M | -687.0K | -6.67M | -2.83M | -2.25M | -2.51M | -3.25M |
| Cash from financing | 150.9M | 97.1M | 73.9M | -897.0K | 267.4M | 495.0M | 100.5M | -24.0K | 197.2M |
| Share buybacks | -221.0K | 0 | 0 | -141.0K | -24.0K | 197.2M | |||
| Change in cash | 10.2M | -27.6M | -48.0M | -139.9M | 27.3M | 323.6M | -23.3M | -123.9M | 119.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Nov 20, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Nov 19, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 9, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| S-4 · Registration statement | Nov 3, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 13, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 2, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 24, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2026 | Current report | SEC |
| 8-K · Current report | Jun 2, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| 424B3 · Prospectus | Apr 15, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 17, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Mar 16, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 12, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 12, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 10, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Mar 10, 2026 | Annual report | SEC |
| 10-K · Annual report | Mar 10, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| 8-K · Current report | Feb 23, 2026 | Material contract | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Dec 15, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| S-3/A · Registration statement, amended | Dec 9, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 5, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 10, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 14, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Sep 30, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 30, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 424B3 · Prospectus | Jul 10, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 7, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jun 30, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 5, 2025 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Jun 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 19, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 9, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 27, 2025 | Annual report | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2024 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Sep 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Sep 23, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 13, 2024 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 14, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 9, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 9, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 18, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| 3 · Initial statement of ownership | Jun 6, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 6, 2024 | Insider trade | SEC |
| 8-K · Current report | May 14, 2024 | Current report | SEC |
| 4 · Change in ownership | May 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2024 | Insider trade | SEC |
| 8-K · Current report | May 8, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | May 7, 2024 | Other filings | SEC |
| 424B5 · Prospectus | May 7, 2024 | Offer document | SEC |
| 424B5 · Prospectus | May 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2024 | Results | SEC |
| SC 13G · Big-stake notice | May 3, 2024 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 25, 2024 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 9, 2024 | Current report | SEC |
| 424B3 · Prospectus | Mar 15, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Mar 15, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 15, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 15, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 15, 2024 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 13, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 13, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 13, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | Mar 13, 2024 | Annual report | SEC |
| 10-K · Annual report | Mar 13, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2024 | Results | SEC |
| 8-K · Current report | Mar 5, 2024 | Current report | SEC |
| 8-K · Current report | Feb 29, 2024 | Management or board change | SEC |
This page holds 200 of 444 filings. Open Filings
Cap table
Built by 6ix from ADC Therapeutics SA’s releases · as of Oct 8, 2026
- Common shares
- 127,667,695
- Fully diluted
- 127,667,695
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 127,667,695 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 127,667,695 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Azelby Other companies: Tango Therapeutics, Inc. (Chairman; Former President and CEO, Eliem Therapeutics, Inc. · Since at least Jun 19, 2026); Autolus Therapeutics plc (Member of the Audit Committee, Member of the Nominating and Governance Committee · Since at least Mar 18, 2026); Terns Pharmaceuticals, Inc. (Director · Since at least Feb 20, 2025); Cardinal Health, Inc. (Director · Since at least Mar 1, 2024); Aduro Biotech Inc (Director · Apr 10, 2023 – Aug 11, 2023 · Past); Climb Bio, Inc. (President & CEO, Director · Aug 9, 2021 – Oct 31, 2022 · Past); Immunomedics Inc (Director · Feb 26, 2020 – Oct 23, 2020 · Past); Clovis Oncology Inc (Director · Oct 11, 2018 – Jun 10, 2021 · Past); Alder BioPharmaceuticals Inc (President and CEO, Director · Jun 13, 2018 – Oct 22, 2019 · Past); Cascadian Therapeutics Inc (Director · Mar 31, 2017 – Mar 9, 2018 · Past); Juno Therapeutics Inc (EVP & Chief Commercial Officer · Nov 1, 2015 – Mar 5, 2018 · Past) | Director · Since at least Jan 2, 2024 |
| Timothy P. Coughlin Other companies: Vir Biotechnology, Inc. (Director · Since at least Jun 9, 2026); aTyr Pharma, Inc. (Chairman · Since at least Apr 7, 2017); Travere Therapeutics, Inc. (Director · Since at least Mar 31, 2015); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Jun 7, 2024 · Past); Neurocrine Biosciences, Inc. (Chief Financial Officer · Sep 18, 2006 – Feb 6, 2017 · Past) | Director · Since at least Jun 3, 2025 |
| Jean-Pierre Bizzari Other companies: Aprea Therapeutics, Inc. (Director · Since at least Aug 23, 2023); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jan 25, 2020 · Past); Celator Pharmaceuticals Inc (Director · Feb 27, 2015 – Jul 12, 2016 · Past); Halozyme Therapeutics, Inc. (Director · Jan 17, 2015 – May 5, 2023 · Past) | Non-Executive Director · Since at least Jan 2, 2024 |
| Ron Squarer Other companies: Nuvalent, Inc. (Director · Since at least Dec 10, 2025); Travere Therapeutics, Inc. (Director · Since at least Apr 10, 2017); Deciphera Pharmaceuticals LLC (Director · Dec 4, 2019 – Jun 11, 2024 · Past); Hospira Inc (Chief Commercial Officer · Jan 7, 2009 – Feb 24, 2011 · Past) | Director · Since at least Jan 2, 2024 |
| Jose Carmona Other companies: Rubius Therapeutics Inc (Chief Financial Officer · Oct 1, 2020 – Jan 31, 2022 · Past); Radius Health, Inc. (Chief Financial Officer · May 15, 2017 – Feb 26, 2020 · Past); Innocoll AG (CFO · Jan 1, 2017 – Jan 1, 2017 · Past) | Chief Financial Officer · Since at least Jan 2, 2024 |
| Peter Graham Other companies: Antares Pharma Inc (See Remarks · Jul 14, 2015 – May 24, 2022 · Past); Delcath Systems, Inc. (EVP; General Counsel · Apr 20, 2010 – Nov 14, 2013 · Past); AngioDynamics, Inc. (Director · Jan 16, 2006 – Oct 25, 2006 · Past) | Chief Legal Officer · Since at least Jan 2, 2024 |
| Tyrell J. Rivers Other companies: Viela Bio Inc (Director · Oct 2, 2019 – Mar 15, 2021 · Past); PhaseBio Pharmaceuticals Inc (Director · Oct 17, 2018 – Oct 17, 2018 · Past); G1 Therapeutics Inc (Director · May 16, 2017 – May 16, 2017 · Past) | Non-Executive Director · Since at least Jan 2, 2024 |
| Victor Sandor Other companies: AbCellera Biologics Inc. (Director · Since at least Jun 1, 2026); Kymera Therapeutics, Inc. (Director · Since at least Nov 3, 2022); Prelude Therapeutics Incorporated (Director · Since at least Sep 24, 2020) | Non-Executive Director · Since at least Jan 2, 2024 |
| Ameet Mallik Other companies: Atara Biotherapeutics, Inc. (Director · Since at least Aug 9, 2021); Rafael Holdings, Inc. (Director · May 1, 2021 – Feb 1, 2022 · Past) | Chief Executive Officer · Since at least Jan 2, 2024 |
| Ron Squarer Other companies: Travere Therapeutics, Inc. (Director · Since at least May 21, 2026); Nuvalent, Inc. (Director · Since at least Dec 10, 2025) | Chairman · Since at least Jun 3, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Viviane Monges Other companies: Pharvaris N.V. (Director, Audit Chair · Since at least Mar 17, 2026); DBV Technologies SA (Director · Jan 1, 2021 – Jun 10, 2021 · Past) | Non-Executive Director · Since at least Jan 2, 2024 |
| Tim Coughlin Other companies: Travere Therapeutics, Inc. (Director · Since at least Jun 16, 2026) | Non-Executive Director · Since at least Jun 3, 2026 |
| Bob Azelby | Non-Executive Director · Since at least Jun 3, 2026 |
| David Ege | Chief Technical Officer · Since at least Nov 5, 2026 |
| Kimberly Pope | Chief People Officer · Since at least Nov 5, 2026 |
| Kristen Harrington-Smith | Chief Commercial Officer · Since at least Nov 5, 2026 |
| Lisa Michelle Kallebo | Chief Accounting Officer · Since at least Jan 2, 2024 |
| Mohamed Zaki | Chief Medical Officer · Since at least Jan 2, 2024 |
| Peter Hug | Vice-Chairman and Lead Independent Director · Since at least Jan 2, 2024 |
| Thomas Pfisterer | Director · Jan 2, 2024 – Jun 17, 2024 · Past |
Log in to ask 6ix AI your own questions about ADC Therapeutics SA.